SCHEMBL968506

SCHEMBL968506

CCC(N)C(=O)N[C@H](CCC(=O)O)C(N)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DPP4 P27487 2/20 0.47
▸ DPP8 Q6V1X1 2/20 0.47
▸ DPP9 Q86TI2 2/20 0.47
▸ NOD1 Q9Y239 1/20 0.47
▸ DPP7 Q9UHL4 1/20 0.43
▸ FOLH1 Q04609 1/20 0.42
▸ RIMKLA Q8IXN7 1/20 0.42
▸ NAALAD2 Q9Y3Q0 1/20 0.42
▸ CA12 O43570 1/20 0.41
▸ CA1 P00915 1/20 0.41
▸ CA9 Q16790 1/20 0.41
▸ ERAP2 Q6P179 1/20 0.41
▸ ERAP1 Q9NZ08 1/20 0.41
▸ LNPEP Q9UIQ6 1/20 0.41
▸ GABRP O00591 2/20 0.41
▸ GABRD O14764 2/20 0.41
▸ GABRA1 P14867 2/20 0.41
▸ GABRB1 P18505 2/20 0.41
▸ GABRG2 P18507 2/20 0.41
▸ GABRB3 P28472 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2419068 1.00 DPP4 (0.47) DPP4DPP8DPP9NOD1DPP7
Hydrochloric Acid SCHEMBL14762334 0.98 DPP4 (0.46) DPP4DPP8DPP9NOD1DPP7
Hydrochloric Acid SCHEMBL14762338 0.98 DPP4 (0.46) DPP4DPP8DPP9NOD1DPP7
SCHEMBL26352136 0.88 FOLH1 (0.56) DPP4DPP8DPP9NOD1FOLH1
SCHEMBL29399742 0.88 FOLH1 (0.56) DPP4DPP8DPP9NOD1FOLH1
SCHEMBL29972744 0.88 DPP4 (0.56) DPP4DPP8DPP9NOD1FOLH1
SCHEMBL11300197 0.86 DPP9 (0.51) DPP4DPP8DPP9NOD1DPP7
SCHEMBL10379810 0.85 DPP4 (0.45) DPP4DPP8DPP9NOD1FOLH1
SCHEMBL13879071 0.85 DPP4 (0.45) DPP4DPP8DPP9NOD1FOLH1
SCHEMBL17793208 0.85 DPP4 (0.53) DPP4DPP8DPP9NOD1FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390053-A2 HCG FORMULATION Acevedo, Hernan F. (US) 2004-02-25 — — EP claimed
WO-2002085311-A2 HCG FORMULATION ACEVEDO HERNAN F (US) 2002-10-31 — — WO claimed
US-8653049-B2 Normuramyl glycopeptide compounds IMUTHES LIMITED (GB) 2014-02-18 — — US disclosed
EP-2578598-A1 Componds derived from normuramyldipeptide IMUTHES LIMITED (GB) 2013-04-10 — — EP disclosed
US-20110002983-A1 COMPOUND IMUTHES LIMITED (GB) 2011-01-06 — — US disclosed
EP-1390053-A2 HCG FORMULATION Acevedo, Hernan F. (US) 2004-02-25 — — EP disclosed
WO-2002085311-A2 HCG FORMULATION ACEVEDO HERNAN F (US) 2002-10-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110002983-A1 COMPOUND C5AR1, C5AR2, ARG1 DPP4 1315/4885DPP8 2109/4885DPP9 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback